Navigation Links
BioMarin to Host First Quarter 2011 Financial Results Conference Call and Webcast on Thursday, April 28 at 5:00 p.m. ET
Date:3/28/2011

NOVATO, Calif., March 28, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 28, at 5:00 p.m. ET to discuss first quarter 2011 financial results.U.S. / Canada Dial-in Number:  888.396.2386International Dial-in Number:  617.847.8712Participant Code: 42725170Replay Dial-in Number: 888.286.8010Replay International Dial-in Number: 617.801.6888Replay Code: 56138656Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

Contacts:
Investors
Eugenia Shen
BioMarin Pharmaceutical Inc.
(415) 506-6570Media
Bob Purcell
BioMarin Pharmaceutical Inc.
(415) 506-3267


'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarin to Host Third Quarter 2010 Financial Results Conference Call and Webcast on Thursday, October 28 at 5:00 p.m. ET
2. BioMarin to Present at the Barclays Capital Global Healthcare Conference
3. BioMarins Chief Executive Jean-Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times
4. BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
5. BioMarin to Present at the Morgan Stanley Healthcare Conference
6. BioMarin to Present at the Baird Healthcare Conference
7. BioMarin to Present at the Jefferies Healthcare Conference
8. BioMarin to Present at the Goldman Sachs Healthcare Conference
9. BioMarin to Present at the Deutsche Bank Health Care Conference
10. BioMarin to Present at the Baird Growth Stock Conference
11. BioMarin Announces First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Corporation (NASDAQ: VWR), the leading global independent provider of product ... its financial results for the fourth quarter and full year ... 4Q16 record quarterly net sales of $1.13 billion, up ... 4Q16 EMEA-APAC segment net sales increased ... net sales increased 2.5%, or down 0.9% on an organic ...
(Date:2/23/2017)... 2017 /PRNewswire/ - The Fight Against Cancer Innovation Trust ... are pleased to report that Fusion Pharmaceuticals Inc. (Fusion) ... & Johnson Innovation – JJDC, Inc. (JJDC) as the ... TPG Biotechnology Partners, and Genesys Capital, as well as ... ...
(Date:2/23/2017)... ... 23, 2017 , ... Brain Sentinel, Inc. has received US ... System, the Brain Sentinel® Seizure Monitoring and Alerting System. The adjunctive seizure monitoring ... of rest. A lightweight, non-invasive monitor is placed on the belly of the ...
(Date:2/23/2017)... 2017  Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company ... announced that Linda Marbán, Ph.D, president and chief executive officer, ... Cowen and Company 37th Annual Health Care ... Boston, MA 29th Annual ... (12:00 pm ET) Dana Point, CA ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 2, 2017  EyeLock LLC, a market leader ... white paper " What You Should Know About Biometrics ... ensuring user authenticity is a growing concern. In traditional ... users. However, traditional authentication schemes such as username/password suffer ... Biometric authentication offers an elegant solution to the problem ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market ... for Biometrics and Digital Identity".  Acuity characterizes 2017 ... identity when increased adoption reflects a new understanding ... "Biometrics and digital identity are often ... Maxine Most , Principal of Acuity Market ...
Breaking Biology News(10 mins):